Holen Sie sich die Stockscreener-App
20.29
4.16%
-0.88
Handel nachbörslich:
20.29
Schlusskurs vom Vortag:
$21.17
Offen:
$21.09
24-Stunden-Volumen:
2.47M
Relative Volume:
2.72
Marktkapitalisierung:
$1.39B
Einnahmen:
$9.98M
Nettoeinkommen (Verlust:
$-154.08M
KGV:
-7.8643
EPS:
-2.58
Netto-Cashflow:
$-159.66M
1W Leistung:
-1.02%
1M Leistung:
+2.58%
6M Leistung:
-20.09%
1J Leistung:
-46.17%
1-Tages-Spanne:
$20.17
$21.54
1-Wochen-Bereich:
$20.17
$22.11
52-Wochen-Spanne:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Vergleichen Sie CLDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
20.29 | 1.39B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Celldex stock price target maintained at $50 by H.C. Wainwright - Investing.com Canada
Global Personalized Cancer Vaccine Market | Immunotherapy - openPR.com
Q2 Earnings Estimate for CLDX Issued By Lifesci Capital - Defense World
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded - Asianet Newsable
Celldex Therapeutics (NASDAQ:CLDX) Earns “Buy” Rating from HC Wainwright - Defense World
Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025 - MarketScreener
Celldex Presents Data Demonstrating Profound Long Term - GlobeNewswire
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire Inc.
Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Targ - GuruFocus
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges By Investing.com - Investing.com South Africa
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges - Investing.com
Celldex Therapeutics Inc (CLDX) Stock: A Comprehensive 52-Week Review - investchronicle.com
Celldex shares jump on impressive skin disorder drug data By Investing.com - Investing.com Canada
Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Target | CLDX Stock News - GuruFocus
Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data - Endpoints News
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Benzinga
Celldex stock maintains Overweight rating on promising CSU therapy results By Investing.com - Investing.com Canada
Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics - Benzinga
Celldex Presents Unprecedented 76 Week Results from - GlobeNewswire
Transcript : Celldex Therapeutics, Inc.Special Call - marketscreener.com
Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com
Celldex (CLDX) Unveils Promising Data for Barzolvolimab in Treating Chronic Urticaria | CLDX Stock News - GuruFocus
Breakthrough: Celldex CSU Drug Maintains Complete Response 7 Months After Treatment Ends - Stock Titan
Celldex stock rating reiterated at Buy by Canaccord ahead of data release - Investing.com Nigeria
One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - simplywall.st
Eric Sprott buying at Silver Storm Mining (SVRS) - The Globe and Mail
Analysts Set Expectations for CLDX FY2026 Earnings - Defense World
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress - GlobeNewswire
Groundbreaking 76-Week Chronic Urticaria Treatment Data: Celldex's Barzolvolimab Results Coming to EAACI - Stock Titan
Celldex Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Celldex Therapeutics Appoints Denice Torres To Board - citybiz
Celldex Therapeutics appoints new board member - Investing.com
Celldex Approves Equity Plan Amendment and Elects New Director - TipRanks
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors - Yahoo Finance
Prurigo Nodularis Pipeline 2025: FDA Updates, Therapy - openPR.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth By Investing.com - Investing.com South Africa
Global Cholera Vaccines Market in 2025-2032 Detailed Study - openPR.com
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth - Investing.com India
BNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Morgan Stanley Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $43.00 - Defense World
UBS Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $38.00 - Defense World
The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00 - Defense World
Hsbc Holdings PLC Takes $233,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics Q1 2025 Earnings: EPS of ($0.81) Misses Est - GuruFocus
UBS Lowers Price Target for Celldex Therapeutics (CLDX) to $38 | - GuruFocus
First Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
H.C. Wainwright cuts Celldex stock price target to $50 from $80 - Investing.com Nigeria
Celldex Therapeutics (CLDX): Analyst Lowers Price Target But Mai - GuruFocus
Morgan Stanley Updates Price Target for Celldex Therapeutics (CL - GuruFocus
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):